BJE6-106 (B106) is a potent and selective PKCδ inhibitor with an IC50 of 0.05 μM, exhibiting 1000-fold selectivity over PKCα (IC50 = 50 μM); it induces caspase-dependent apoptosis and demonstrates tumor-specific activity; it suppresses cell survival in melanoma cell lines harboring NRAS mutations; it activates the MKK4-JNK-H2AX pathway by inducing phosphorylation of MKK4, JNK, and H2AX in SBcl2 cells.